Key result
Si-Miao-Yong-An decoction significantly improved cardiac function, increased left ventricle ejection fraction, and decreased fibrosis area in a mouse model of heart failure.
Why the study?
Although Si-Miao-Yong-An decoction is clinically used for cardiovascular diseases in China, its mechanisms in preventing heart failure are not fully revealed.
Does Si-Miao-Yong-An decoction improve cardiac fibrosis and ventricular remodeling in mice with pressure overload-induced heart failure?
Population
Mice subjected to transverse aorta constriction
Comparison
SMYAD (14.85 g/kg/day) vs captopril (16.5 mg/kg/day)
Design
Animal experimental study
Follow-up
4 weeks
Authors
Loading...
Supports preclinical antifibrotic effects of SMYAD in pressure-overload HF; hypothesis-generating and should not yet change practice.
Does Si-Miao-Yong-An decoction improve cardiac fibrosis and ventricular remodeling in mice with pressure overload-induced heart failure?
Si-Miao-Yong-An decoction attenuates cardiac fibrosis and improves cardiac function in a mouse model of pressure overload by inhibiting the TGF-β1/Smad and TGF-β1/TAK1/p38 pathways.
Su et al. (2020) studied Heart failure and cardiac remodeling. Si-Miao-Yong-An decoction (SMYAD) vs. Captopril (16.5 mg/kg/day) and TAC control was evaluated on Cardiac function, left ventricle ejection fraction, and fibrosis area. Si-Miao-Yong-An decoction significantly improved cardiac function, increased left ventricle ejection fraction, and decreased fibrosis area in a mouse model of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: